JAK INHIBITORS IN SYSTEMIC SCLEROSIS: A SCOPING REVIEW
PDF
Cite
Share
Request
Invited Review
P: 0-0

JAK INHIBITORS IN SYSTEMIC SCLEROSIS: A SCOPING REVIEW

Rheumatol Q 0;0(0):0-0
1. Dokuz Eylül University Faculty of Medicine, Department of Rheumatology, İzmir, Turkey
No information available.
No information available
Received Date: 06.08.2023
Accepted Date: 14.08.2023
PDF
Cite
Share
Request

ABSTRACT

Systemic sclerosis (SSc) is a rare multisystemic chronic immune-mediated rheumatic disease. Although it is not common, it still has the highest mortality and morbidity rate among the systemic rheumatic diseases. This review aimed to analyze the results of multiple preclinical trials and clinical data about Janus kinase (JAK) inhibitors in SSc treatment and provides a comprehensive overview of JAK inhibitors as a new treatment option in SSc.

Keywords: Systemic sclerosis, JAK inhibitors, tofacitinib, baricitinib, ruxolitinib

References

2024 ©️ Galenos Publishing House